GlassScriptPhysician profile
Abdul M Orra
NPI 1053474320
$21,075.09
in general payments reported to CMS, 2019-2025
60 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,625 · 2020: $2,885 · 2021: $3,379 · 2022: $2,963 · 2023: $3,006 · 2024: $3,288 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,202 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,202.16 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,242.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,770.96 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,702.06 | 2019-2025 | |
| Lilly USA, LLC | $1,380.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,298.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,164.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,124.51 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $943.39 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $856.22 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Merck Sharp & Dohme LLC | $786.10 | 2019-2025 | Verquvo, Capvaxive, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $745.44 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $647.23 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $482.20 | 2019-2020 | |
| Amarin Pharma, INC. | $443.82 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $438.64 | 2019-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Orra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.